These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11733645)

  • 1. Is the use of subcutaneous epoetin beta once a week really equivalent to a more frequent administration of the same total dose?
    Andrulli S; D'Amico M; Locatelli F
    Nephrol Dial Transplant; 2001 Dec; 16(12):2439-40. PubMed ID: 11733645
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.
    Weiss LG; Clyne N; Divino Fihlho J; Frisenette-Fich C; Kurkus J; Svensson B
    Nephrol Dial Transplant; 2000 Dec; 15(12):2014-9. PubMed ID: 11096148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients.
    Lago M; Pérez-García R; García de Vinuesa MS; Anaya F; Valderrábano F
    Nephron; 1996; 72(4):723-4. PubMed ID: 8730458
    [No Abstract]   [Full Text] [Related]  

  • 5. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 6. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study.
    Locatelli F; Baldamus CA; Villa G; Ganea A; Martín de Francisco AL
    Am J Kidney Dis; 2002 Jul; 40(1):119-25. PubMed ID: 12087569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).
    Levin NW; Fishbane S; Cañedo FV; Zeig S; Nassar GM; Moran JE; Villa G; Beyer U; Oguey D;
    Lancet; 2007 Oct; 370(9596):1415-21. PubMed ID: 17950856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of changing s.c. epoetin alfa administration from thrice weekly to once weekly in hemodialysis patients.
    To LL; Stoner CP
    Am J Health Syst Pharm; 2003 May; 60(9):931-4. PubMed ID: 12756944
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and efficacy of multidose epoetin beta (Reco-Pen) for subcutaneous administration in patients with anemia due to renal failure.
    Kleophas W; Kult J; Kreusser W; Piper C; Plache H; Wunderle P; Fiegel V; Härtl W;
    Kidney Blood Press Res; 2003; 26(3):192-8. PubMed ID: 12886047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.
    McMahon LP; Dawborn JK
    Am J Nephrol; 1990; 10(5):404-8. PubMed ID: 2080791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.